Skip to main content

Shawn Heidel

SVP, Early Development - Greenfield, IN

317-361-5342

Areas of Support:  Early Development

Memberships: Society of Toxicology, American College of Toxicology

Publications: 

  • Sewell F, Chapman K, Couch J, Dempster M, Heidel S, Loberg L, Maier C, Maclachlan TK, Todd M, van der Laan JW. Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use. MAbs. 2017; 9(5):742-755.
  • Ponce RA, Gelzleichter T, Haggerty HG, Heidel S, Holdren MS, Lebrec H, Mellon RD, Pallardy M. Immunomodulation and Lymphoma in Humans. J Immunotoxicol. 2014; 11(1): 1-12.
  • Rudmann DG, Alston JT, Hanson JC, Heidel S. High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation is Molecular Weight Dependent and Does Not Require Conjugation to Proteins. Toxicol Pathol. 2013. 41(7): 970-983.
  • Vahle JL, Finch GL, Heidel SM, Hovland SN, Ivens I, Parker S, Ponce RA, Sachs C, Steigerwalt R, Short B, Todd M. Carcinogenicity Assessments of Biotechnology-derived Pharmaceuticals: A Review of Approved Molecules and Best Practice Recommendations. 
    Toxicologic Pathology, 2010. 38: 522-553.
  • Nakazawa T, Kurokawa M, Kimura K, Wakata A, Hisada S, Inoue T, Sagami F, Heidel SM, Kawakami K, Shinoda K, Onodera H, Kumagai Y, Ohno Y, Kawamura N, Yamazaki T, Inoue T. Safety Assessment of Biopharmaceuticals: Japanese Perspective on ICH S6 guideline Maintenance. 2008 Aug; 33(3):277-82.
    Heidel SM, Page T. Current practices in the preclinical toxicity evaluation of peptides.
    Book Chapter in “Preclinical Safety Evaluation of Biopharmaceuticals.” Editor: Joy Cavagnaro. 2008. John Wiley and Sons.
  • Clarke J, Hurst C, Martin P, Vahle J, Ponce R, Mounho B, Heidel S, Andrews L, Reynolds T, Cavagnaro J. Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: Is 6 months still appropriate? Regul Toxicol Pharmacol. 2008 Feb; 50(1):2-22. Epub 2007 Aug 24.
  • Vick A, Wolff R, Koester A, Reams R, Deaver DR, Heidel S.
    A 6-month inhalation study to characterize the toxicity, pharmacokinetics, and pharmacodynamics of human insulin inhalation powder (HIIP) in beagle dogs.
    J Aerosol Med. 2007 Summer;20(2):112-26.
  • Heidel SM.Genetic toxicology and carcinogenicity assessments of Biologic Drugs.
    Regulatory and Safety Evaluation Specialty Section Newsletter, SOT.
    Summer, 2005.
  • Czuprynski CJ, Page TJ, O’Brien SA, MacWilliams PS, Holston K, Jefcoate CR, Heidel SM. 
    DMBA-induced bone marrow toxicity is p53 dependent. Toxicol Sci, 2001, S1813.
  • Heidel SM, MacWilliams PS, Baird WM, Dashwood WM, Buters JT, Gonzalez FJ, Larsen MC, Czuprynski CJ, Jefcoate CR. Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7, 12-dimethylbenz[a]anthracene.
    Cancer Res. 2000 Jul 1; 60(13):3454-60.
  • Heidel SM, MacWilliams PS, Baird WM, Dashwood WM, Buters JTM, Gonzalez FJ, Larsen MC, Galvan N, Czuprynski CJ, Jefcoate CR. Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and pre-leukemia cells in mice treated with 7,12-dimethylbenz[a]anthracene. Toxicological Sciences, 2000, S483.
  • Heidel SM, Holston K, Buters JT, Gonzalez FJ, Jefcoate CR, Czupyrynski CJ.
    Bone marrow stromal cell cytochrome P4501B1 is required for pre-B cell apoptosis induced by 7, 12-dimethylbenz[a]anthracene. Mol Pharmacol. 1999 Dec; 56(6):1317-23.
  • Heidel SM, Czuprynski CJ, Jefcoate CR. Bone marrow stromal cells constitutively express high levels of cytochrome P4501B1 that metabolize 7, 12-dimethylbenz[a]anthracene.
    Mol Pharmacol. 1998 Dec; 54(6):1000-6.
  • Heidel SM, Czuprynski CJ, Jefcoate CR. Primary bone marrow stromal cell expression of DMBA-metabolizing CYP1B1 is dependent on the AhR. Toxicological Sciences, 1998, S145.
  • Heidel SM, Czuprynski CJ, Jefcoate CR. Metabolism of DMBA by CYP1B1 in bone marrow stromal cells is influenced by the Ah receptor. Fundamental and Applied Toxicology, 1997, S1001.
  • Hsieh JT, Denning MF, Heidel SM, Verma AK. Expression of human chromosome 2 ornithine decarboxylase gene in ornithine decarboxylase-deficient Chinese hamster ovary cells.
    Cancer Res. 1990 Apr 15; 50(8):2239-44. Erratum

Education: DVM, PhD in Immunotoxicology - University of Wisconsin